Pages that link to "Q38329899"
Jump to navigation
Jump to search
The following pages link to Gedske Daugaard (Q38329899):
Displaying 50 items.
- Muscle dysfunction in cancer patients (Q26822365) (← links)
- Prostate cancer: ESMO Consensus Conference Guidelines 2012 (Q27022847) (← links)
- The Danish Testicular Cancer database (Q28069310) (← links)
- No AZF deletion in 160 patients with testicular germ cell neoplasia (Q28191777) (← links)
- Increased risk of myelodysplasia and leukaemia after etoposide, cisplatin, and bleomycin for germ-cell tumours (Q28323966) (← links)
- Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer. (Q33383770) (← links)
- Paclitaxel, cisplatin and gemcitabine in treatment of carcinomas of unknown primary site, a phase II study (Q33389172) (← links)
- Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986 (Q33398722) (← links)
- Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. (Q33399928) (← links)
- Effects of antineoplastic treatment of HIV-positive patients with testicular cancer (Q33414650) (← links)
- Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial (Q33419283) (← links)
- Safety and efficacy of resistance training in germ cell cancer patients undergoing chemotherapy: a randomized controlled trial (Q33877463) (← links)
- The International Testicular Cancer Linkage Consortium: a clinicopathologic descriptive analysis of 461 familial malignant testicular germ cell tumor kindred (Q33937556) (← links)
- Progressive resistance training and cancer testis (PROTRACT) - efficacy of resistance training on muscle function, morphology and inflammatory profile in testicular cancer patients undergoing chemotherapy: design of a randomized controlled trial. (Q33977589) (← links)
- Testicular cancer survivorship: research strategies and recommendations (Q34039684) (← links)
- Randomized phase III study comparing paclitaxel-bleomycin, etoposide, and cisplatin (BEP) to standard BEP in intermediate-prognosis germ-cell cancer: intergroup study EORTC 30983. (Q34136937) (← links)
- The Y deletion gr/gr and susceptibility to testicular germ cell tumor (Q34137428) (← links)
- European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). (Q34342158) (← links)
- European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I. (Q34735176) (← links)
- A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-cell cancer. An intergroup study of EORTC, GTCSG, and Grupo Germin (Q34854106) (← links)
- Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract (Q34997941) (← links)
- Analysis of the DND1 gene in men with sporadic and familial testicular germ cell tumors (Q35030350) (← links)
- Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer. (Q35063446) (← links)
- Endocrine function in patients treated for carcinoma in situ in the testis with irradiation (Q35129476) (← links)
- Cancers of unknown primary origin (CUP) are characterized by chromosomal instability (CIN) compared to metastasis of know origin (Q35503657) (← links)
- Evaluation of nephrotoxicity secondary to cytostatic agents (Q35651086) (← links)
- Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. (Q35879087) (← links)
- Carcinoma in situ testis, the progenitor of testicular germ cell tumours: a clinical review (Q36093911) (← links)
- A prospective comparison of 18F-FDG PET/CT and CT as diagnostic tools to identify the primary tumor site in patients with extracervical carcinoma of unknown primary site (Q36251449) (← links)
- Severe intracellular magnesium and potassium depletion in patients after treatment with cisplatin (Q36671514) (← links)
- Outcome of patients with HIV-related germ cell tumours: a case-control study. (Q36694972) (← links)
- Somatic mutations of KIT in familial testicular germ cell tumours (Q36697196) (← links)
- Treatment with docetaxel and cisplatin in advanced adrenocortical carcinoma, a phase II study (Q36896065) (← links)
- European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II. (Q37055475) (← links)
- 18F-FDG PET/CT as a diagnostic tool in patients with extracervical carcinoma of unknown primary site: a literature review (Q37856041) (← links)
- Treatment options for carcinoma in situ testis. (Q37886265) (← links)
- Salvage therapy: SIU/ICUD Consensus Meeting on Germ Cell Tumors (GCT), Shanghai 2009. (Q37943997) (← links)
- The contemporary role of chemotherapy for advanced testis cancer: a systematic review of the literature. (Q37998642) (← links)
- Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA. (Q38373171) (← links)
- At what price do we treat patients with testicular cancer? (Q38555904) (← links)
- Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. (Q38706310) (← links)
- Differences in global DNA methylation of testicular seminoma are not associated with changes in histone modifications, clinical prognosis, BRAF mutations or gene expression (Q38728982) (← links)
- Cisplatin nephrotoxicity. A review (Q38730217) (← links)
- Testosterone deficiency in testicular cancer survivors - a systematic review and meta-analysis. (Q38786676) (← links)
- Surveillance versus adjuvant radiotherapy for patients with high-risk stage I seminoma (Q38789849) (← links)
- Imaging response during therapy with radium-223 for castration-resistant prostate cancer with bone metastases-analysis of an international multicenter database. (Q38937691) (← links)
- Paclitaxel/carboplatin with or without belinostat as empiric first-line treatment for patients with carcinoma of unknown primary site: A randomized, phase 2 trial (Q39051716) (← links)
- Impact of primary metastatic bone disease in germ cell tumors: results of an International Global Germ Cell Tumor Collaborative Group G3 Registry Study. (Q39086345) (← links)
- Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial (Q39125659) (← links)
- Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC). (Q39303051) (← links)